<DOC>
	<DOCNO>NCT00135967</DOCNO>
	<brief_summary>Patients idiopathic membranous nephropathy renal insufficiency risk end-stage renal disease ( ESRD ) . Treatment cyclophosphamide currently use treatment modality . Mycophenolate mofetil new immunosuppressive agent few side effect . In pilot study patient membranous nephropathy renal failure treat mycophenolate mofetil prednisone . The outcome compare historical control treat similar regimen contain cyclophosphamide .</brief_summary>
	<brief_title>Mycophenolate Mofetil Membranous Nephropathy</brief_title>
	<detailed_description />
	<mesh_term>Kidney Diseases</mesh_term>
	<mesh_term>Glomerulonephritis , Membranous</mesh_term>
	<mesh_term>Glomerulonephritis</mesh_term>
	<mesh_term>Prednisolone acetate</mesh_term>
	<mesh_term>Methylprednisolone acetate</mesh_term>
	<mesh_term>Prednisone</mesh_term>
	<mesh_term>Methylprednisolone</mesh_term>
	<mesh_term>Methylprednisolone Hemisuccinate</mesh_term>
	<mesh_term>Prednisolone</mesh_term>
	<mesh_term>Prednisolone hemisuccinate</mesh_term>
	<mesh_term>Prednisolone phosphate</mesh_term>
	<mesh_term>Mycophenolic Acid</mesh_term>
	<mesh_term>Mycophenolate mofetil</mesh_term>
	<criteria>Membranous nephropathy Serum creatinine ( Screat ) &gt; 1,5 mg/dl ECC &lt; 70 ml/min increase Screat &gt; 50 % Proteinuria &gt; 2 g/day Systemic disease Pregnancy wish Active infection Liver dysfunction Abnormal hematology lab Unstable angina Nonsteroidal antiinflammatory agent ( NSAIDs )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>August 2005</verification_date>
	<keyword>membranous nephropathy</keyword>
	<keyword>mycophenolate mofetil</keyword>
	<keyword>cyclophosphamide</keyword>
	<keyword>prednisone</keyword>
</DOC>